NCT04609176 2023-04-21
Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Peking University
Phase 2 Unknown
Clinical Trials
9 trialsNCT05111444 2021-11-08
Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Fudan University
Phase 2 Unknown
NCT05095636 2021-10-27
Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer
Fudan University
Phase 2 Unknown
NCT04889768 2021-05-17
HIPEC Combined With Camrelizumab, Paclitaxel and S-1 for Conversion Therapy in Patients With Advanced Gastric Cancer With Peritoneal Metastasis
Zhejiang Cancer Hospital
Phase NA Unknown
NCT04631757 2020-11-17
Conversion Therapy of Camrelizumab Plus Chemoradiotherapy in Participants With Initial Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT04367025 2020-04-29
Efficacy and Safety of Perioperative Chemotherapy Plus PD-1 Antibody in Gastric Cancer
Chinese PLA General Hospital
Phase 2 Unknown
NCT04152889 2020-04-20
A Study to Evaluate Camrelizumab in Combination With Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer
RenJi Hospital
Phase 2 Unknown
NCT04345783 2020-04-14
Efficacy and Safety of Camrelizumab for Injection, Apatinib Mesylate and Tegio for First-line Refractory Patients With Advanced Gastric Cancer
Beijing Friendship Hospital
Phase 2 Unknown
NCT02942329 2018-02-26
Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Phase 1/2 Unknown